Patient Gateway

RSS Feed

Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II to IIIB NSCLC

ELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC

ELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC

Dr Gerber on the Neurocognitive Tradeoffs of Later-Generation ALK TKIs in NSCLC

Adjuvant Ensartinib Improves DFS in Resected ALK-Positive NSCLC

Adjuvant Ensartinib Improves DFS in Resected ALK-Positive NSCLC

Adjuvant immunotherapy in resected non-small cell lung cancer harboring oncogenic driver alterations beyond EGFR and ALK: results from a retrospective analysis

Anaplastic lymphoma kinase (ALK) fusion oncogene positive non small cell lung cancer

Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.